Home » Newsletters » BioWorld Science

BioWorld Science

March 20, 2002

View Archived Issues

Neotrofin protects against neurodegeneration in a rat model of Parkinson's disease

Once-weekly antidepressant safe and effective in natural clinical setting

Inhibition of UL70 primase as a promising approach to the treatment of cytomegalovirus infections

QYL-1064 and analogues effective against cytomegalovirus and certain other herpesviruses

UMJD-1369 identified as a potent, early-acting anti-HCMV pyrrolopyrimidine

Results reported in Barcelona for DNA and protein AutoVac HER-2 vaccines

Ezetimibe further improves lipoprotein profiles in statin-treated hypercholesterolemic patients

Compounds that prevent peptide metabolism reported by Sumitomo

Sankyo describes novel immunosuppressants in a recent patent

Steroid sulfatase inhibitors disclosed by Nippon Organon

Scientists at Aventis describe a new series of antidiabetic compounds

Melacure Therapeutics discloses melanocortin receptor ligands and their use

Novel LPS inhibitors synthesized at Mitsubishi Pharma

Ligand reports on 2001 highlights

Inex offers 2001 update

Swiss approval and launch of Tracleer announced

Amersham Health reports good progress in a number of areas during 2001

Zelnorm/Zelmac approved in Canada and Brazil

deCODE completes MediChem acquisition

Health Canada approves expanded label for ProstaScint

Boston Life Sciences initiates phase II study of Altropane for ADHD diagnosis

PowderJect to sell drug business to AlgoRx

PH-50 uptake in animal soft plaque tissue encouraging for early diagnosis of coronary artery disease

Encouraging results emerge from pilot phase III trial of Chronogesic

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...